Menu Search
Equities

PDL BioPharma Inc

PDL:HAM

PDL BioPharma Inc

Actions
  • Price (EUR)2.12
  • Today's Change-0.01 / -0.47%
  • Shares traded0.00
  • 1 Year change-5.49%
  • Beta0.6083
Data delayed at least 15 minutes, as of Oct 17 2019 07:03 BST.
More ▼

Profile data is unavailable for this security.

About the company

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

  • Revenue in USD (TTM)129.40m
  • Net income in USD44.10m
  • Incorporated1986
  • Employees107.00
  • Location
    PDL BioPharma Inc932 Southwood BlvdINCLINE VILLAGE 89451United StatesUSA
  • Phone+1 (775) 832-8500
  • Fax+1 (775) 832-8501
  • Websitehttp://www.pdl.com
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.